CyanVac selects Exothera for the development and GMP manufacturing of its COVID-19 intranasal vaccine candidate for phase III clinical trial in Europe and the US Mar 24 Written By Guest User Read the press release from Exothera here. Guest User
CyanVac selects Exothera for the development and GMP manufacturing of its COVID-19 intranasal vaccine candidate for phase III clinical trial in Europe and the US Mar 24 Written By Guest User Read the press release from Exothera here. Guest User
